European pharmaceutical marketing leader Medis has signed a distribution agreement with Indian drug maker Lupin for the latter’s orphan drug mexiletin (NaMuscla). Under the agreement,  Medis will commercialize NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries. According to Lupin, NaMuscla is the first and only licensed product for NDM disorders, a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction. This drug reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients. NaMuscla, which has been currently designated as an orphan drug, received EU marketing authorization in December 2018.